Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2017 May 3;13(5):e1006368.
doi: 10.1371/journal.ppat.1006368. eCollection 2017 May.

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

Published Erratum

Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

Sergio Serrano-Villar et al. PLoS Pathog. .

Abstract

[This corrects the article DOI: 10.1371/journal.ppat.1005381.].

PubMed Disclaimer

Figures

Fig 7
Fig 7. Tissue drug distribution.
Panels A-B. Rectum/plasma (A) and duodenum/plasma (B) drug concentration ratios. The tissue concentrations converted to ng/mL assuming a tissue density of 1.06 g/mL. Maraviroc reached the highest distribution to rectum and duodenum (all P<0.005). Panel C-E. Correlations between plasma, rectum and duodenal levels of EFV (C),MVC(D) and RAL (E). MVC plasma levels correlated better with tissue levels than RAL or EFV.
Fig 9
Fig 9
Absolute concentrations in each compartment of efavirenz (A), maraviroc (B) and raltegravir (C) related to the IC50 for HIV-1 replication. The tissue concentrations converted to ng/mL assuming a tissue density of 1.06 g/mL.

Erratum for

References

    1. Serrano-Villar S, Sainz T, Ma Z-M, Utay NS, Wook-Chun T, Mann S, et al. (2016) Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathog 12(1): e1005381 doi:10.1371/journal.ppat.1005381 - DOI - PMC - PubMed

Publication types